The role of microRNAs in the regulation of apoptosis in lung cancer and its application in cancer treatment

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Othman, Norahayu ^a   Nagoor, Noor Hasima ^a,b  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEMCITABINE; MICRORNA; MICRORNA 100; MICRORNA 101; MICRORNA 133A; MICRORNA 133B; MICRORNA 143; MICRORNA 146A; MICRORNA 17 5P; MICRORNA 192; MICRORNA 197; MICRORNA 198; MICRORNA 203; MICRORNA 20A; MICRORNA 21; MICRORNA 212; MICRORNA 26A; MICRORNA 31; MICRORNA 335; MICRORNA 361 3P; MICRORNA 451; MICRORNA 608; MICRORNA 650; MICRORNA 7; PACLITAXEL; PROTEIN BCL 2; PROTEIN KINASE C; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TUMOR MARKER;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CANCER THERAPY; CHEMOSENSITIVITY; GENE TARGETING; GENETIC REGULATION; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; NONHUMAN; ONCOGENE; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICRORNAS; TUMOR MARKERS, BIOLOGICAL;

EID: 84903649764     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/318030     Document Type: Article

References (175)

1. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 2014 International Agency for Search on Cancer. World Health Organization
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M. J., Cancer statistics, 2008. CA: Cancer Journal for Clinicians 2008 58 2 71 96 2-s2.0-41349099104 10.3322/CA.2007.0010 (Pubitemid 351521864)
3. Molina J. R., Yang P., Cassivi S. D., Schild S. E., Adjei A. A., Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic Proceedings 2008 83 5 584 594 2-s2.0-44249086425 10.4065/83.5.584 (Pubitemid 351720831)
4. Pfister D. G., Johnson D. H., Azzoli C. G., Sause W., Smith T. J., Baker S. Jr., Olak J., Stover D., Strawn J. R., Turrisi A. T., Somerfield M. R., American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. Journal of Clinical Oncology 2004 22 2 330 353 2-s2.0-1342268525 10.1200/JCO.2004.09.053 (Pubitemid 41095099)
5. SEER Cancer Statistics Review 1975-2010. Surveillance 2013 Epidemiology, and End Results Program. National Cancer Institute
6. Sorenson C. M., Bcl-2 family members and disease. Biochimica et Biophysica Acta 2004 1644 2-3 169 177 2-s2.0-1442359844 10.1016/j.bbamcr.2003. 08.010 (Pubitemid 38281273)
7. Hanahan D., Weinberg R. A., Hallmarks of cancer: the next generation. Cell 2011 144 5 646 674 2-s2.0-79952284127 10.1016/j.cell.2011.02.013
8. Wang X. W., Harris C. C., p53 tumor-suppressor gene: clues to molecular carcinogenesis. Journal of Cellular Physiology 1997 173 247 255 (Pubitemid 27481139)
9. Daniel J. C., Smythe W. R., The role of Bcl-2 family members in non-small cell lung cancer. Seminars in Thoracic and Cardiovascular Surgery 2004 16 1 19 27 2-s2.0-2642555698 (Pubitemid 38714756)
10. Fisher T. C., Milner A. E., Gregory C. D., Jackman A. L., Aherne G. W., Hartley J. A., Dive C., Hickman J. A., bcl-2 Modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Research 1993 53 14 3321 3326 2-s2.0-0027279128 (Pubitemid 23223304)
11. Miyashita T., Reed J. C., Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993 81 1 151 157 2-s2.0-0027389763 (Pubitemid 23013689)
12. Tang C., Willingham M. C., Reed J. C., Miyashita T., Ray S., Ponnathpur V., Huang Y., Mahoney M. E., Bullock G., Bhalla K., High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 1994 8 11 1960 1969 2-s2.0-0028029834
13. Bartel D. P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004 116 2 281 297 2-s2.0-0347444723 10.1016/S0092-8674(04)00045-5 (Pubitemid 38167318)
14. Lewis B. P., Burge C. B., Bartel D. P., Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005 120 1 15 20 2-s2.0-11844278458 10.1016/j.cell.2004.12.035 (Pubitemid 40094598)
15. Calin G. A., Dumitru C. D., Shimizu M., Bichi R., Zupo S., Noch E., Aldler H., Rattan S., Keating M., Rai K., Rassenti L., Kipps T., Negrini M., Bullrich F., Croce C. M., Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America 2002 99 24 15524 15529 2-s2.0-18744396337 10.1073/pnas.242606799 (Pubitemid 35403967)
16. Cimmino A., Calin G. A., Fabbri M., Iorio M. V., Ferracin M., Shimizu M., Wojcik S. E., Aqeilan R. I., Zupo S., Dono M., Rassenti L., Alder H., Volinia S., Liu C.-G., Kipps T. J., Negrini M., Croce C. M., miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences of the United States of America 2005 102 39 13944 13949 2-s2.0-25444520537 10.1073/pnas.0506654102 (Pubitemid 41377683)
17. Han J., Goldstein L. A., Gastman B. R., Rabinowich H., Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. The Journal of Biological Chemistry 2006 281 15 10153 10163 2-s2.0-33744507693 10.1074/jbc.M510349200 (Pubitemid 43864551)
18. Volinia S., Calin G. A., Liu C.-G., Ambs S., Cimmino A., Petrocca F., Visone R., Iorio M., Roldo C., Ferracin M., Prueitt R. L., Yanaihara N., Lanza G., Scarpa A., Vecchione A., Negrini M., Harris C. C., Croce C. M., A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America 2006 103 7 2257 2261 2-s2.0-33144490646 10.1073/pnas.0510565103 (Pubitemid 43271657)
19. He L., He X., Lim L. P., De Stanchina E., Xuan Z., Liang Y., Xue W., Zender L., Magnus J., Ridzon D., Jackson A. L., Linsley P. S., Chen C., Lowe S. W., Cleary M. A., Hannon G. J., A microRNA component of the p53 tumour suppressor network. Nature 2007 447 7148 1130 1134 2-s2.0-34250851115 10.1038/nature05939 (Pubitemid 47014436)
20. Mott J. L., Kobayashi S., Bronk S. F., Gores G. J., mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007 26 42 6133 6140 2-s2.0-34548687035 10.1038/sj.onc.1210436 (Pubitemid 47414372)
21. Woods K., Thomson J. M., Hammond S. M., Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. The Journal of Biological Chemistry 2007 282 4 2130 2134 2-s2.0-34047264639 10.1074/jbc.C600252200 (Pubitemid 47076737)
22. Tsang W. P., Kwok T. T., Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis 2008 13 10 1215 1222 2-s2.0-51749088101 10.1007/s10495-008-0256-z
23. Wiemer E. A. C., The role of microRNAs in cancer: no small matter. European Journal of Cancer 2007 43 10 1529 1544 2-s2.0-34250201468 10.1016/j.ejca.2007.04.002 (Pubitemid 46901017)
24. Calin G. A., Liu C.-G., Sevignani C., Ferracin M., Felli N., Dumitru C. D., Shimizu M., Cimmino A., Zupo S., Dono M., Dell'Aquila M. L., Alder H., Rassenti L., Kipps T. J., Bullrich F., Negrini M., Croce C. M., MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proceedings of the National Academy of Sciences of the United States of America 2004 101 32 11755 11760 2-s2.0-4143142117 10.1073/pnas.0404432101 (Pubitemid 39095368)
25. Iorio M. V., Ferracin M., Liu C.-G., Veronese A., Spizzo R., Sabbioni S., Magri E., Pedriali M., Fabbri M., Campiglio M., Ménard S., Palazzo J. P., Rosenberg A., Musiani P., Volinia S., Nenci I., Calin G. A., Querzoli P., Negrini M., Croce C. M., MicroRNA gene expression deregulation in human breast cancer. Cancer Research 2005 65 16 7065 7070 2-s2.0-23844555119 10.1158/0008-5472.CAN-05-1783 (Pubitemid 41161233)
26. + breast cancers from patients receiving adjuvant Tamoxifen mono-therapy: a DBCG study. PLoS ONE 2012 7 5 2-s2.0-84862109179 10.1371/journal.pone.0036170 e36170
27. Ciafrè S. A., Galardi S., Mangiola A., Ferracin M., Liu C.-G., Sabatino G., Negrini M., Maira G., Croce C. M., Farace M. G., Extensive modulation of a set of microRNAs in primary glioblastoma. Biochemical and Biophysical Research Communications 2005 334 4 1351 1358 2-s2.0-23044464236 10.1016/j.bbrc.2005.07.030 (Pubitemid 41074723)
28. Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., Stephens R. M., Okamoto A., Yokota J., Tanaka T., Calin G. A., Liu C.-G., Croce C. M., Harris C. C., Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006 9 3 189 198 2-s2.0-33644819964 10.1016/j.ccr.2006.01.025 (Pubitemid 43357945)
29. Jovanovic M., Hengartner M. O., miRNAs and apoptosis: RNAs to die for. Oncogene 2006 25 46 6176 6187 2-s2.0-33749528151 10.1038/sj.onc.1209912 (Pubitemid 44527848)
30. Lima R. T., Busacca S., Almeida G. M., Gaudino G., Fennell D. A., Vasconcelos M. H., MicroRNA regulation of core apoptosis pathways in cancer. European Journal of Cancer 2011 47 2 163 174 2-s2.0-78650686123 10.1016/j.ejca.2010.11.005
31. Li C., Hashimi S. M., Good D. A., Cao S., Duan W., Plummer P. N., Mellick A. S., Wei M. Q., Apoptosis and microRNA aberrations in cancer. Clinical and Experimental Pharmacology and Physiology 2012 39 8 739 746 2-s2.0-84864312441 10.1111/j.1440-1681.2012.05700.x
32. Wang Y., Lee C. G. L., MicroRNA and cancer-focus on apoptosis. Journal of Cellular and Molecular Medicine 2009 13 1 12 23 2-s2.0-58649107855 10.1111/j.1582-4934.2008.00510.x
33. Son J. W., Kim Y. J., Cho H. M., Lee S. Y., Jang J. S., Choi J. E., Lee J. U., Kang M. G., Lee Y. M., Kwon S. J., Choi E., Na M. J., Park J. Y., MicroRNA expression profiles in Korean non-small cell lung cancer. Tuberculosis and Respiratory Diseases 2009 67 5 413 421 2-s2.0-74049110561 10.4046/trd.2009.67.5.413
34. Miska E. A., How microRNAs control cell division, differentiation and death. Current Opinion in Genetics and Development 2005 15 5 563 568 2-s2.0-24344494340 10.1016/j.gde.2005.08.005 (Pubitemid 41262414)
35. Fiori M. E., Barbini C., Haas T. L., Marroncelli N., Patrizii M., Biffoni M., De Maria R., Antitumor effect of miR-197 targeting in p53 wild-type lung cancer. Cell Death & Differentiation 2014 21 5 774 782 10.1038/cdd.2014.6
36. Puthalakath H., Villunger A., O'Reilly L. A., Beaumont J. G., Coultas L., Cheney R. E., Huang D. C. S., Strasser A., Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 2001 293 5536 1829 1832 2-s2.0-0035823238 10.1126/science. 1062257 (Pubitemid 32845780)
37. Hatley M. E., Patrick D. M., Garcia M. R., Richardson J. A., Bassel-Duby R., van Rooij E., Olson E. N., Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 2010 18 3 282 293 2-s2.0-77956501846 10.1016/j.ccr.2010.08.013
38. Kim D.-M., Chung K.-S., Choi S.-J., Jung Y.-J., Park S.-K., Han G.-H., Ha J.-S., Song K.-B., Choi N.-S., Kim H.-M., Won M., Seo Y.-S., RhoB induces apoptosis via direct interaction with TNFAIP1 in HeLa cells. International Journal of Cancer 2009 125 11 2520 2527 2-s2.0-70350721797 10.1002/ijc.24617
39. Ye W., Gong X., Xie J., Wu J., Zhang X., Ouyang Q., Zhao X., Shi Y., AChE deficiency or inhibition decreases apoptosis and p53 expression and protects renal function after ischemia/reperfusion. Apoptosis 2010 15 4 474 487 2-s2.0-77951665874 10.1007/s10495-009-0438-3
40. Zhang X., Lu L., Liu S., Ye W., Wu J., Zhang X., Acetylcholinesterase deficiency decreases apoptosis in dopaminergic neurons in the neurotoxin model of Parkinson's disease. International Journal of Biochemistry & Cell Biology 2013 45 2 265 272 2-s2.0-84872287422 10.1016/j.biocel.2012.11.015
41. Zhang X. J., Yang L., Zhao Q., Caen J. P., He H. Y., Jin Q. H., Guo L. H., Alemany M., Zhang L. Y., Shi Y. F., Induction of acetylcholinesterase expression during apoptosis in various cell types. Cell Death & Differentiation 2002 9 8 790 800 2-s2.0-0036024019 10.1038/sj.cdd.4401034
42. Zhao Y., Wang X., Wang T., Hu X., Hui X., Yan M., Gao Q., Chen T., Li J., Yao M., Wan D., Gu J., Fan J., He X., Acetylcholinesterase, a key prognostic predictor for hepatocellular carcinoma, suppresses cell growth and induces chemosensitization. Hepatology 2011 53 2 493 503 2-s2.0-79251470088 10.1002/hep.24079
43. Lu L., Zhang X., Zhang B., Wu J., Zhang X., Synaptic acetylcholinesterase targeted by microRNA-212 functions as a tumor suppressor in non-small cell lung cancer. The International Journal of Biochemistry & Cell Biology 2013 45 2530 2540
44. Hayashita Y., Osada H., Tatematsu Y., Yamada H., Yanagisawa K., Tomida S., Yatabe Y., Kawahara K., Sekido Y., Takahashi T., A polycistronic MicroRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Research 2005 65 21 9628 9632 2-s2.0-27544495514 10.1158/0008-5472.CAN-05-2352 (Pubitemid 41541436)
45. Matsubara H., Takeuchi T., Nishikawa E., Yanagisawa K., Hayashita Y., Ebi H., Yamada H., Suzuki M., Nagino M., Nimura Y., Osada H., Takahashi T., Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92. Oncogene 2007 26 41 6099 6105 2-s2.0-34447101200 10.1038/sj.onc.1210425 (Pubitemid 47373805)
46. O'Donnell K. A., Wentzel E. A., Zeller K. I., Dang C. V., Mendell J. T., c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005 435 7043 839 843 2-s2.0-20444479428 10.1038/nature03677 (Pubitemid 40839736)
47. MacLeod K., pRb and E2f-1 in mouse development and tumorigenesis. Current Opinion in Genetics and Development 1999 9 1 31 39 2-s2.0-0033040967 10.1016/S0959-437X(99)80005-7 (Pubitemid 29080384)
48. Zhang B., Pan X., Cobb G. P., Anderson T. A., microRNAs as oncogenes and tumor suppressors. Developmental Biology 2007 302 1 1 12 2-s2.0-33846188098 10.1016/j.ydbio.2006.08.028 (Pubitemid 46096921)
49. Ruan K., Fang X., Ouyang G., MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Letters 2009 285 2 116 126 2-s2.0-70349976210 10.1016/j.canlet.2009.04.031
50. Hockenbery D. M., Zutter M., Hickey W., Nahm M., Korsmeyer S. J., BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proceedings of the National Academy of Sciences of the United States of America 1991 88 16 6961 6965 2-s2.0-0025835716 (Pubitemid 21915069)
51. Xiong S., Zheng Y., Jiang P., Liu R., Liu X., Chu Y., MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. International Journal of Biological Sciences 2011 7 6 805 814 2-s2.0-79960983743
52. Wang H., Li M., Zhang R., Wang Y., Zang W., Ma Y., Zhao G., Zhang G., Effect of miR-335 upregulation on the apoptosis and invasion of lung cancer cell A549 and H1299. Tumor Biology 2013 34 3101 3109 2-s2.0-84878389335 10.1007/s13277-013-0878-9
53. Dynan W. S., Tjian R., The promoter-specific transcription factor Sp 1 binds to upstream sequences in the SV40 early promoter. Cell 1983 35 1 79 87 2-s2.0-0021058853 (Pubitemid 14240221)
54. Suske G., Bruford E., Philipsen S., Mammalian SP/KLF transcription factors: bring in the family. Genomics 2005 85 5 551 556 2-s2.0-16244405603 10.1016/j.ygeno.2005.01.005 (Pubitemid 40463690)
55. Othman N., In L. L. A., Harikrishna J. A., Hasima N., Bcl-xL silencing induces alterations in hsa-miR-608 expression and subsequent cell death in A549 and SK-LU1 human lung adenocarcinoma cells. PLoS ONE 2013 8 12 10.1371/journal.pone.0081735 e81735
56. Soini Y., Kinnula V., Kaarteenaho-Wiik R., Kurttila E., Linnainmaa K., Pääkkö P., Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma. Clinical Cancer Research 1999 5 11 3508 3515 2-s2.0-0032758427
57. Nishizuka Y., Protein kinase C and lipid signaling for sustained cellular responses. FASEB Journal 1995 9 7 484 496 2-s2.0-0029060391
58. Liu W. S., Heckman C. A., The sevenfold way of PKC regulation. Cellular Signalling 1998 10 8 529 542 2-s2.0-0031786125 10.1016/S0898-6568(98)00012-6 (Pubitemid 28438329)
59. Livneh E., Fishman D. D., Linking protein kinase c to cell-cycle control. European Journal of Biochemistry 1997 248 1 1 9 2-s2.0-0030795939 (Pubitemid 27356962)
60. Clark A. S., West K. A., Blumberg P. M., Dennis P. A., Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKC δ promotes cellular survival and chemotherapeutic resistance. Cancer Research 2003 63 4 780 786 2-s2.0-0037443030 (Pubitemid 36231976)
61. Wang C., Wang X., Lian H., Wang T., Yan X., Cao M., Wang N., Zhang S., Zen K., Zhang C., Chen X., miR-203 inhibits cell proliferation and migration of lung cancer cells by targeting PKC α PLoS ONE 2013 8 9 10.1371/journal.pone.0073985 e73985
62. Akita Y., Protein kinase C- ε (PKC- ε): its unique structure and function. Journal of Biochemistry 2002 132 6 847 852 2-s2.0-0036956424 (Pubitemid 36090649)
63. Zhang N., Su Y., Xu L., Targeting PKCe by miR-143 regulates cell apoptosis in lung cancer. FEBS Letters 2013 587 3661 3667
64. McJilton M. A., Van Sikes C., Wescott G. G., Wu D., Foreman T. L., Gregory C. W., Weidner D. A., Ford O. H., Lasater A. M., Mohler J. L., Terrian D. M., Protein kinase C ε interacts with Bax and promotes survival of human prostate cancer cells. Oncogene 2003 22 39 7958 7968 2-s2.0-0345549478 10.1038/sj.onc.1206795 (Pubitemid 37175861)
65. Ding L., Wang H., Lang W., Xiao L., Protein kinase C- ε promotes survival of lung cancer cells by suppressing apoptosis through dysregulation of the mitochondrial caspase pathway. The Journal of Biological Chemistry 2002 277 38 35305 35313 2-s2.0-0037144492 10.1074/jbc.M201460200
66. Sivaprasad U., Shankar E., Basu A., Downregulation of Bid is associated with PKC ε -mediated TRAIL resistance. Cell Death & Differentiation 2007 14 4 851 860 2-s2.0-33947418962 10.1038/sj.cdd.4402077 (Pubitemid 46444522)
67. Okhrimenko H., Lu W., Xiang C., Hamburger N., Kazimirsky G., Brodie C., Protein kinase C- ε regulates the apoptosis and survival of glioma cells. Cancer Research 2005 65 16 7301 7309 2-s2.0-23844474726 10.1158/0008-5472.CAN- 05-1064 (Pubitemid 41161262)
68. Wu D., Thakore C. U., Wescott G. G., McCubrey J. A., Terrian D. M., Integrin signaling links protein kinase C ε to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells. Oncogene 2004 23 53 8659 8672 2-s2.0-9644259240 10.1038/sj.onc.1207900 (Pubitemid 39576473)
69. Yang J., Zhao H., Xin Y., Fan L., MicroRNA-198 inhibits proliferation and induces apoptosis of lung cancer cells via targeting FGFR1. Journal of Cellular Biochemistry 2013 115 5 987 995 10.1002/jcb.24742
70. Chen G., Umelo I. A., Lv S., Teugels E., Fostier K., Kronenberger P., Dewaele A., Sadones J., Geers C., De Grève J., miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. PLoS ONE 2013 8 3 2-s2.0-84875424861 10.1371/journal.pone.0060317 e60317
71. Dang X., Ma A., Yang L., Hu H., Zhu B., Shang D., Chen T., Luo Y., MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. Cancer Genetics 2012 205 3 113 123 2-s2.0-84860255370 10.1016/j.cancergen.2012.01.002
72. Cao Q., Yu J., Dhanasekaran S. M., Kim J. H., Mani R.-S., Tomlins S. A., Mehra R., Laxman B., Cao X., Yu J., Kleer C. G., Varambally S., Chinnaiyan A. M., Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008 27 58 7274 7284 2-s2.0-57649124289 10.1038/onc.2008.333
73. Xie D., Gore C., Zhou J., Pong R.-C., Zhang H., Yu L., Vessella R. L., Min W., Hsieh J.-T., DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis. Proceedings of the National Academy of Sciences of the United States of America 2009 106 47 19878 19883 2-s2.0-73949154866 10.1073/pnas.0908458106
74. Wei D., Gong W., Oh S. C., Li Q., Kim W. D., Wang L., Le X., Yao J., Wu T. T., Huang S., Xie K., Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Research 2005 65 11 4809 4816 2-s2.0-21144440536 10.1158/0008-5472.CAN-04-3741 (Pubitemid 40740819)
75. Wang R., Wang Z.-X., Yang J.-S., Pan X., De W., Chen L.-B., MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene 2011 30 23 2644 2658 2-s2.0-79958288052 10.1038/onc.2010.642
76. Feng S., Cong S., Zhang X., Bao X., Wang W., Li H., Wang Z., Wang G., Xu J., Du B., Qu D., Xiong W., Yin M., Ren X., Wang F., He J., Zhang B., MicroRNA-192 targeting retinoblastoma 1 inhibits cell proliferation and induces cell apoptosis in lung cancer cells. Nucleic Acids Research 2011 39 15 6669 6678 2-s2.0-80055080741 10.1093/nar/gkr232
77. Ebi H., Sato T., Sugito N., Hosono Y., Yatabe Y., Matsuyama Y., Yamaguchi T., Osada H., Suzuki M., Takahashi T., Counterbalance between RB inactivation and miR-17-92 overexpression in reactive oxygen species and DNA damage induction in lung cancers. Oncogene 2009 28 38 3371 3379 2-s2.0-70349464806 10.1038/onc.2009.201
78. Chang A., Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011 71 1 3 10 2-s2.0-78650236850 10.1016/j.lungcan.2010.08.022
79. Lynam-Lennon N., Maher S. G., Reynolds J. V., The roles of microRNA in cancer and apoptosis. Biological Reviews 2009 84 1 55 71 2-s2.0-58849139162 10.1111/j.1469-185X.2008.00061.x
80. Schiller J. H., Harrington D., Belani C. P., Langer C., Sandler A., Krook J., Zhu J., Johnson D. H., Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England Journal of Medicine 2002 346 2 92 98 2-s2.0-0037050352 10.1056/NEJMoa011954 (Pubitemid 34438899)
81. Wang G., Reed E., Li Q. Q., Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer. Oncology Reports 2004 12 5 955 965 2-s2.0-16544374489
82. Eaton K. D., Martins R. G., Maintenance chemotherapy in non-small cell lung cancer. JNCCN Journal of the National Comprehensive Cancer Network 2010 8 7 815 821 2-s2.0-77955389435
83. Szakács G., Paterson J. K., Ludwig J. A., Booth-Genthe C., Gottesman M. M., Targeting multidrug resistance in cancer. Nature Reviews Drug Discovery 2006 5 3 219 234 2-s2.0-33644775686 10.1038/nrd1984 (Pubitemid 43336035)
84. Bian H.-B., Pan X., Yang J.-S., Wang Z.-X., De W., Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). Journal of Experimental and Clinical Cancer Research 2011 30 1, article 20 2-s2.0-79952539094 10.1186/1756-9966-30-20
85. Glavinas H., Krajcsi P., Cserepes J., Sarkadi B., The role of ABC transporters in drug resistance, metabolism and toxicity. Current Drug Delivery 2004 1 1 27 42 2-s2.0-2542491777
86. Dong Z., Zhong Z., Yang L., Wang S., Gong Z., MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9. Cancer Letters 2014 343 249 257
87. Mcguire W. P., Hoskins W. J., Brady M. F., Kucera P. R., Partridge E. E., Look K. Y., Clarke-Pearson D. L., Davidson M., Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. The New England Journal of Medicine 1996 334 1 1 6 2-s2.0-0030054309 10.1056/NEJM199601043340101 (Pubitemid 26012496)
88. Henderson I. C., Berry D. A., Demetri G. D., Cirrincione C. T., Goldstein L. J., Martino S., Ingle J. N., Cooper M. R., Hayes D. F., Tkaczuk K. H., Fleming G., Holland J. F., Duggan D. B., Carpenter J. T., Frei E. III, Schilsky R. L., Wood W. C., Muss H. B., Norton L., Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. Journal of Clinical Oncology 2003 21 6 976 983 2-s2.0-0037445132 10.1200/JCO.2003.02.063 (Pubitemid 46594124)
89. Bonomi P., Kim K., Fairclough D., Cella D., Kugler J., Rowinsky E., Comparison of survival for stage IIIB versus stage IV non-small cell lung cancer (NSCLC) patients with etoposide-cisplatin versus taxol-cisplatin: an Eastern Cooperative Oncology Group (ECOG) trial. 16 Proceedings of American Society of Clinical Oncology 1997 454a
90. Belani C. P., Lee J., Socinski M. A., Robert F., Waterhouse D., Rowland K., Ansari R., Lilenbaum R., Natale R. B., Randomized phase III trial comparing cisplatin/etopside versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC). 17 Proceedings of American Society of Clinical Oncology 1998 455a
91. Du L., Borkowski R., Zhao Z., Ma X., Yu X., Xie X.-J., Pertsemlidis A., A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel. RNA Biology 2013 10 1700 1713
92. Karanikolas B. D. W., Figueiredo M. L., Wu L., Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines. Prostate 2010 70 6 675 688 2-s2.0-77950874502 10.1002/pros.21112
93. Sellers W. R., Loda M., The EZH2 polycomb transcriptional repressor-a marker or mover of metastatic prostate cancer? Cancer Cell 2002 2 5 349 350 2-s2.0-0038002683 10.1016/S1535-6108(02)00187-3 (Pubitemid 41039099)
94. Kleer C. G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S. A., Ghosh D., Sewalt R. G. A. B., Otte A. P., Hayes D. F., Sabel M. S., Livant D., Weiss S. J., Rubin M. A., Chinnaiyan A. M., EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proceedings of the National Academy of Sciences of the United States of America 2003 100 20 11606 11611 2-s2.0-0141816752 10.1073/pnas.1933744100 (Pubitemid 37205983)
95. Wagener N., Holland D., Bulkescher J., Crnković-Mertens I., Hoppe-Seyler K., Zentgraf H., Pritsch M., Buse S., Pfitzenmaier J., Haferkamp A., Hohenfellner M., Hoppe-Seyler F., The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells. International Journal of Cancer 2008 123 7 1545 1550 2-s2.0-50549103560 10.1002/ijc.23683
96. Ougolkov A. V., Bilim V. N., Billadeau D. D., Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clinical Cancer Research 2008 14 21 6790 6796 2-s2.0-58149214373 10.1158/1078-0432.CCR-08-1013
97. Kikuchi J., Kinoshita I., Shimizu Y., Kikuchi E., Konishi J., Oizumi S., Kaga K., Matsuno Y., Nishimura M., Dosaka-Akita H., Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Cancer 2010 116 12 3015 3024 2-s2.0-77953978709 10.1002/cncr.25128
98. Zhang J.-G., Guo J.-F., Liu D.-L., Liu Q., Wang J.-J., MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. Journal of Thoracic Oncology 2011 6 4 671 678 2-s2.0-79953029421 10.1097/JTO.0b013e318208eb35
99. Yvon A.-M. C., Wadsworth P., Jordan M. A., Taxol suppresses dynamics of individual microtubules in living human tumor cells. Molecular Biology of the Cell 1999 10 4 947 959 2-s2.0-0032933622 (Pubitemid 29193723)
100. Lyseng-Williamson K. A., Fenton C., Docetaxel: a review of its use in metastatic breast cancer. Drugs 2005 65 17 2513 2531 2-s2.0-28144445570 10.2165/00003495-200565170-00007 (Pubitemid 41697318)
101. Rui W., Bing F., Hai-Zhu S., Wei D., Long-Bang C., Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1). Journal of Cellular and Molecular Medicine 2010 14 1-2 206 214 2-s2.0-77951945516 10.1111/j.1582-4934.2009.00964.x
102. Feng B., Wang R., Chen L.-B., MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Letters 2012 317 2 184 191 2-s2.0-84856595853 10.1016/j.canlet.2011.11.024
103. Eckerdt F., Yuan J., Strebhardt K., Polo-like kinases and oncogenesis. Oncogene 2005 24 2 267 276 2-s2.0-13244269808 10.1038/sj.onc.1208273 (Pubitemid 40188607)
104. Wolf G., Elez R., Doermer A., Holtrich U., Ackermann H., Stutte H. J., Altmannsberger H.-M., Rübsamen-Waigmann H., Strebhardt K., Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997 14 5 543 549 2-s2.0-0031051218 (Pubitemid 27090956)
105. Huang J.-Y., Cui S.-Y., Chen Y.-T., Song H.-Z., Huang G.-C., Feng B., Sun M., De W., Wang R., Chen L.-B., MicroRNA-650 was a prognostic factor in human lung adenocarcinoma and confers the docetaxel chemoresistance of lung adenocarcinoma cells via regulating Bcl-2/Bax expression. PLoS ONE 2013 8 8 2-s2.0-84882602688 10.1371/journal.pone.0072615 e72615
106. Peters G. J., Van Der Wilt C. L., Van Moorsel C. J. A., Kroep J. R., Bergman A. M., Ackland S. P., Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacology and Therapeutics 2000 87 2-3 227 253 2-s2.0-0033801694 10.1016/S0163-7258(00)00086-3
107. Crinò L., Scagliotti G. V., Ricci S., De Marinis F., Rinaldi M., Gridelli C., Ceribelli A., Bianco R., Marangolo M., Di Costanzo F., Sassi M., Barni S., Ravaioli A., Adamo V., Portalone L., Cruciani G., Masotti A., Ferrara G., Gozzelino F., Tonato M., Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. Journal of Clinical Oncology 1999 17 11 3522 3530 2-s2.0-0032701095 (Pubitemid 29517923)
108. Cardenal F., Paz López-Cabrerizo M., Antón A., Alberola V., Massuti B., Carrato A., Barneto I., Lomas M., García M., Lianes P., Montalar J., Vadell C., González-Larriba J. L., Nguyen B., Artal A., Rosell MD R., Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. Journal of Clinical Oncology 1999 17 1 12 18 2-s2.0-0345148774 (Pubitemid 29022372)
109. Sandler A. B., Nemunaitis J., Denham C., Von Pawel J., Cormier Y., Gatzemeier U., Mattson K., Manegold C., Palmer M. C., Gregor A., Nguyen B., Niyikiza C., Einhorn L. H., Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. Journal of Clinical Oncology 2000 18 1 122 130 2-s2.0-17344384668 (Pubitemid 30036345)
110. Scagliotti G. V., De Marinis F., Rinaldi M., Crinò L., Gridelli C., Ricci S., Matano E., Boni C., Marangolo M., Failla G., Altavilla G., Adamo V., Ceribelli A., Clerici M., Di Costanzo F., Frontini L., Tonato M., Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. Journal of Clinical Oncology 2002 20 21 4285 4291 2-s2.0-0036843105 10.1200/JCO.2002.02.068 (Pubitemid 35266288)
111. Crawford M., Batte K., Yu L., Wu X., Nuovo G. J., Marsh C. B., Otterson G. A., Nana-Sinkam S. P., MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochemical and Biophysical Research Communications 2009 388 3 483 489 2-s2.0-69549101926 10.1016/j.bbrc.2009.07.143
112. Thomadaki H., Scorilas A., BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Critical Reviews in Clinical Laboratory Sciences 2006 43 1 1 67 2-s2.0-33644928489 10.1080/10408360500295626 (Pubitemid 43379211)
113. Song L., Coppola D., Livingston S., Cress D., Haura E. B., Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biology and Therapy 2005 4 3 267 276 2-s2.0-25144453314 (Pubitemid 41351285)
114. Kawasaki T., Yokoi S., Tsuda H., Izumi H., Kozaki K.-I., Aida S., Ozeki Y., Yoshizawa Y., Imoto I., Inazawa J., BCL2L2 is a probable target for novel 14q11.2 amplification detected in a non-small cell lung cancer cell line. Cancer Science 2007 98 7 1070 1077 2-s2.0-34249904163 10.1111/j.1349-7006.2007.00491.x (Pubitemid 46865393)
115. Mendelsohn J., Baselga J., Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. Journal of Clinical Oncology 2003 21 14 2787 2799 2-s2.0-0041629450 10.1200/JCO.2003.01.504 (Pubitemid 46606324)
116. Ciardiello F., Tortora G., Drug therapy: EGFR antagonists in cancer treatment. The New England Journal of Medicine 2008 358 11 1096 1174 2-s2.0-40849147041 10.1056/NEJMra0707704 (Pubitemid 351398490)
117. Yeh P., Chen H., Andrews J., Naser R., Pao W., Horn L., DNA-mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. Clinical Cancer Research 2013 19 7 1894 1901 2-s2.0-84877097462 10.1158/1078-0432.CCR-12-1894
118. Ohashi K., Maruvka Y. E., Michor F., Pao W., Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. Journal of Clinical Oncology 2013 31 8 1070 1080 2-s2.0-84875950992 10.1200/JCO.2012.43.3912
119. Yun C.-H., Boggon T. J., Li Y., Woo M. S., Greulich H., Meyerson M., Eck M. J., Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007 11 3 217 227 2-s2.0-33847406095 10.1016/j.ccr.2006.12.017 (Pubitemid 46349842)
120. Yun C.-H., Mengwasser K. E., Toms A. V., Woo M. S., Greulich H., Wong K.-K., Meyerson M., Eck M. J., The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proceedings of the National Academy of Sciences of the United States of America 2008 105 6 2070 2075 2-s2.0-40049099220 10.1073/pnas.0709662105 (Pubitemid 351439466)
121. Costanzo R., Montanino A., Di Maio M., Piccirillo M. C., Sandomenico C., Giordano P., Daniele G., Franco R., Perrone F., Rocco G., Normanno N., Morabito A., Advanced non small cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives. Expert Review of Anticancer Therapy 2013 13 10 1207 1218 10.1586/14737140.2013.845092
122. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., Gemma A., Harada M., Yoshizawa H., Kinoshita I., Fujita Y., Okinaga S., Hirano H., Yoshimori K., Harada T., Ogura T., Ando M., Miyazawa H., Tanaka T., Saijo Y., Hagiwara K., Morita S., Nukiwa T., Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. The New England Journal of Medicine 2010 362 25 2380 2388 2-s2.0-77953930730 10.1056/NEJMoa0909530
123. Garofalo M., Romano G., Di Leva G., Nuovo G., Jeon Y.-J., Ngankeu A., Sun J., Lovat F., Alder H., Condorelli G., Engelman J. A., Ono M., Rho J. K., Cascione L., Volinia S., Nephew K. P., Croce C. M., EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nature Medicine 2012 18 1 74 82 2-s2.0-84855543629 10.1038/nm.2577
124. Cragg M. S., Kuroda J., Puthalakath H., Huang D. C. S., Strasser A., Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Medicine 2007 4 10 1681 1690 2-s2.0-35648953299 10.1371/journal.pmed.0040316 (Pubitemid 350035457)
125. Deng W.-G., Kwon J., Ekmekcioglu S., Poindexter N. J., Grimm E. A., IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways. Melanoma Research 2011 21 1 44 56 2-s2.0-78649309946 10.1097/CMR.0b013e3283382155
126. Wang Y.-S., Wang Y.-H., Xia H.-P., Zhou S.-W., Schmid-Bindert G., Zhou C.-C., MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines. Asian Pacific Journal of Cancer Prevention 2012 13 1 255 260 2-s2.0-84864865233 10.7314/APJCP.2012.13.1.255
127. Grant S., Qiao L., Dent P., Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci 2002 7 d376 389 2-s2.0-0036479747
128. Chang F., Lee J. T., Navolanic P. M., Steelman L. S., Shelton J. G., Blalock W. L., Franklin R. A., McCubrey J. A., Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003 17 3 590 603 2-s2.0-0037352170 10.1038/sj.leu.2402824 (Pubitemid 36395654)
129. Tamura M., Gu J., Matsumoto K., Aota S.-I., Parsons R., Yamada K. M., Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998 280 5369 1614 1617 2-s2.0-0032486198 10.1126/science.280. 5369.1614 (Pubitemid 28277707)
130. Sulis M. L., Parsons R., PTEN: from pathology to biology. Trends in Cell Biology 2003 13 9 478 483 2-s2.0-0142011466 10.1016/S0962-8924(03)00175-2 (Pubitemid 37289398)
131. Liu L., Shao X., Gao W., Zhang Z., Liu P., Wang R., Huang P., Yin Y., Shu Y., MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor. FEBS Journal 2012 279 20 3800 3812 2-s2.0-84867102786 10.1111/j.1742-4658.2012.08741.x
132. Levine A. J., p53, the cellular gatekeeper for growth and division. Cell 1997 88 3 323 331 2-s2.0-0030941458 10.1016/S0092-8674(00)81871-1 (Pubitemid 27131374)
133. Vogelstein B., Lane D., Levine A. J., Surfing the p53 network. Nature 2000 408 6810 307 310 2-s2.0-0034676455 10.1038/35042675
134. El-Hizawi S., Lagowski J. P., Kulesz-Martin M., Albor A., Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins. Cancer Research 2002 62 11 3264 3270 2-s2.0-0036605971 (Pubitemid 34602423)
135. Olivier M., Eeles R., Hollstein M., Khan M. A., Harris C. C., Hainaut P., The IARC TP53 database: new online mutation analysis and recommendations to users. Human Mutation 2002 19 6 607 614 2-s2.0-0036258111 10.1002/humu.10081 (Pubitemid 34556481)
136. Mitsudomi T., Steinberg S. M., Nau M. M., Carbone D., D'Amico D., Bodner S., Oie H. K., Linnoila R. I., Mulshine J. L., Minna J. D., Gazdar A. F., p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 1992 7 1 171 180 2-s2.0-0026543204
137. Ventura A., Kirsch D. G., McLaughlin M. E., Tuveson D. A., Grimm J., Lintault L., Newman J., Reczek E. E., Weissleder R., Jacks T., Restoration of p53 function leads to tumour regression in vivo. Nature 2007 445 7128 661 665 2-s2.0-33846899456 10.1038/nature05541 (Pubitemid 46232887)
138. Xue W., Zender L., Miething C., Dickins R. A., Hernando E., Krizhanovsky V., Cordon-Cardo C., Lowe S. W., Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007 445 7128 656 660 2-s2.0-33846937033 10.1038/nature05529 (Pubitemid 46232886)
139. Foster B. A., Coffey H. A., Morin M. J., Rastinejad F., Pharmacological rescue of mutant p53 conformation and function. Science 1999 286 5449 2507 2510 2-s2.0-0033601370 10.1126/science.286.5449.2507 (Pubitemid 30026339)
140. Bykov V. J. N., Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., Bergman J., Wiman K. G., Selivanova G., Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nature Medicine 2002 8 3 282 288 2-s2.0-0036128899 10.1038/nm0302-282 (Pubitemid 34250107)
141. Tarasov V., Jung P., Verdoodt B., Lodygin D., Epanchintsev A., Menssen A., Meister G., Hermeking H., Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G 1-arrest. Cell Cycle 2007 6 13 1586 1593 2-s2.0-34250868124 (Pubitemid 47327945)
142. Corney D. C., Flesken-Nikitin A., Godwin A. K., Wang W., Nikitin A. Y., MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Research 2007 67 18 8433 8438 2-s2.0-34548803950 10.1158/0008-5472.CAN-07-1585 (Pubitemid 47437414)
143. Bommer G. T., Gerin I., Feng Y., Kaczorowski A. J., Kuick R., Love R. E., Zhai Y., Giordano T. J., Qin Z. S., Moore B. B., MacDougald O. A., Cho K. R., Fearon E. R., p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Current Biology 2007 17 15 1298 1307 2-s2.0-34547458550 10.1016/j.cub.2007.06.068 (Pubitemid 47176893)
144. Raver-Shapira N., Marciano E., Meiri E., Spector Y., Rosenfeld N., Moskovits N., Bentwich Z., Oren M., Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Molecular Cell 2007 26 5 731 743 2-s2.0-34249822779 10.1016/j.molcel.2007.05.017 (Pubitemid 46856247)
145. Chang T.-C., Wentzel E. A., Kent O. A., Ramachandran K., Mullendore M., Lee K., Feldmann G., Yamakuchi M., Ferlito M., Lowenstein C. J., Arking D., Beer M. A., Maitra A., Mendell J. T., Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Molecular Cell 2007 26 5 745 752 2-s2.0-34249817549 10.1016/j.molcel.2007.05.010 (Pubitemid 46856245)
146. Welch C., Chen Y., Stallings R. L., MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007 26 34 5017 5022 2-s2.0-34249812122 10.1038/sj.onc.1210293 (Pubitemid 47172643)
147. Yamakuchi M., Ferlito M., Lowenstein C. J., miR-34a repression of SIRT1 regulates apoptosis. Proceedings of the National Academy of Sciences of the United States of America 2008 105 36 13421 13426 2-s2.0-51649115553 10.1073/pnas.0801613105
148. Duan W., Gao L., Wu X., Wang L., Nana-Sinkam S. P., Otterson G. A., Villalona-Calero M. A., MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network in human lung cancer cells. International Journal of Cancer 2010 127 2 313 320 2-s2.0-77953715517 10.1002/ijc.25049
149. Kuttan R., Bhanumathy P., Nirmala K., George M. C., Potential anticancer activity of turmeric (Curcuma longa). Cancer Letters 1985 29 2 197 202 2-s2.0-0022357855 (Pubitemid 16175818)
150. Chiu T.-L., Su C.-C., Curcumin inhibits proliferation and migration by increasing the Bax to Bcl-2 ratio and decreasing NF- Bp65 expression in breast cancer MDA-MB-231 cells. International Journal of Molecular Medicine 2009 23 4 469 475 2-s2.0-67649443814 10.3892/ijmm-00000153
151. Johnson S. M., Gulhati P., Arrieta I., Wang X., Uchida T., Gao T., Evers B. M., Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling. Anticancer Research 2009 29 8 3185 3190 2-s2.0-68549083507
152. Chendil D., Ranga R. S., Meigooni D., Sathishkumar S., Ahmed M. M., Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 2004 23 8 1599 1607 2-s2.0-1542426626 10.1038/sj.onc.1207284 (Pubitemid 38406523)
153. Sandur S. K., Ichikawa H., Pandey M. K., Kunnumakkara A. B., Sung B., Sethi G., Aggarwal B. B., Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane). Free Radical Biology and Medicine 2007 43 4 568 580 2-s2.0-34447299398 10.1016/j.freeradbiomed.2007.05.009 (Pubitemid 47058232)
154. Zhang J., Du Y., Wu C., Ren X., Ti X., Shi J., Zhao F., Yin H., Curcumin promotes apoptosis in human lung adenocarcinoma cells through miR-186 signaling pathway. Oncology Reports 2010 24 5 1217 1223 2-s2.0-78149342035 10.3892/or-00000975
155. Choi B. H., Kim C. G., Lim Y., Shin S. Y., Lee Y. H., Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF B pathway. Cancer Letters 2008 259 1 111 118 2-s2.0-36849021582 10.1016/j.canlet.2007.10.003 (Pubitemid 350235095)
156. Simoni D., Rizzi M., Rondanin R., Baruchello R., Marchetti P., Invidiata F. P., Labbozzetta M., Poma P., Carina V., Notarbartolo M., Alaimo A., D'Alessandro N., Antitumor effects of curcumin and structurally β -diketone modified analogs on multidrug resistant cancer cells. Bioorganic and Medicinal Chemistry Letters 2008 18 2 845 849 2-s2.0-38149112614 10.1016/j.bmcl.2007.11. 021
157. Zhang J., Zhang T., Ti X., Shi J., Wu C., Ren X., Yin H., Curcumin promotes apoptosis in A549/DDP multidrug-resistant human lung adenocarcinoma cells through an miRNA signaling pathway. Biochemical and Biophysical Research Communications 2010 399 1 1 6 2-s2.0-77955589719 10.1016/j.bbrc.2010.07.013
158. Zhu W., Xu H., Zhu D., Zhi H., Wang T., Wang J., Jiang B., Shu Y., Liu P., miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemotherapy and Pharmacology 2012 69 3 723 731 2-s2.0-84859779031 10.1007/s00280-011-1752-3
159. Adam L., Zhong M., Choi W., Qi W., Nicoloso M., Arora A., Calin G., Wang H., Siefker-Radtke A., McConkey D., Bar-Eli M., Dinney C., miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clinical Cancer Research 2009 15 16 5060 5072 2-s2.0-69349087756 10.1158/1078-0432.CCR-08-2245
160. Li A., Omura N., Hong S.-M., Vincent A., Walter K., Griffith M., Borges M., Goggins M., Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Research 2010 70 13 5226 5237 2-s2.0-77954354936 10.1158/0008-5472.CAN-09-4227
161. Zhu W., Shan X., Wang T., Shu Y., Liu P., MiR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. International Journal of Cancer 2010 127 11 2520 2529 2-s2.0-77955619456 10.1002/ijc.25260
162. Schaefer U., Voloshanenko O., Willen D., Walczak H., TRAIL: a multifunctional cytokine. Frontiers in Bioscience 2007 12 10 3813 3824 2-s2.0-34347253556 10.2741/2354
163. Falschlehner C., Emmerich C. H., Gerlach B., Walczak H., TRAIL signalling: decisions between life and death. International Journal of Biochemistry & Cell Biology 2007 39 7-8 1462 1475 2-s2.0-34447094000 10.1016/j.biocel.2007.02.007 (Pubitemid 47031030)
164. Garofalo M., Quintavalle C., Di Leva G., Zanca C., Romano G., Taccioli C., Liu C. G., Croce C. M., Condorelli G., MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 2008 27 27 3845 3855 2-s2.0-42749093490 10.1038/onc.2008.6 (Pubitemid 351862062)
165. Rossi G., Cavazza A., Marchioni A., Longo L., Migaldi M., Sartori G., Bigiani N., Schirosi L., Casali C., Morandi U., Facciolongo N., Maiorana A., Bavieri M., Fabbri L. M., Brambilla E., Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFR α PDGFR β and Met in large-cell neuroendocrine carcinoma of the lung. Journal of Clinical Oncology 2005 23 34 8774 8785 2-s2.0-33644840322 10.1200/JCO.2005.02.8233 (Pubitemid 46211523)
166. Dierov J., Xu Q., Dierova R., Carroll M., Tel/platelet-derived growth factor receptor β activates phosphatidylinositol 3 (PI3) kinase and requires PI3 kinase to regulate the cell cycle. Blood 2002 99 5 1758 1765 2-s2.0-0036493405 10.1182/blood.V99.5.1758 (Pubitemid 34533051)
167. Yu J., Deuel T. F., Kim H.-R. C., Platelet-derived growth factor (PDGF) receptor- α activates c-Jun NH2-terminal kinase-1 and antagonizes PDGF receptor- β -induced phenotypic transformation. The Journal of Biological Chemistry 2000 275 25 19076 19082 2-s2.0-0034705427 10.1074/jbc.M910329199 (Pubitemid 30422875)
168. Garofalo M., Di Leva G., Romano G., Nuovo G., Suh S.-S., Ngankeu A., Taccioli C., Pichiorri F., Alder H., Secchiero P., Gasparini P., Gonelli A., Costinean S., Acunzo M., Condorelli G., Croce C. M., miR-221&222 Regulate TRAIL Resistance and Enhance Tumorigenicity through PTEN and TIMP3 Downregulation. Cancer Cell 2009 16 6 498 509 2-s2.0-70949104622 10.1016/j.ccr.2009.10.014
169. Garofalo M., Jeon Y.-J., Nuovo G. J., Middleton J., Secchiero P., Joshi P., Alder H., Nazaryan N., Di Leva G., Romano G., Crawford M., Nana-Sinkam P., Croce C. M., MiR-34a/c-dependent PDGFR- α / β downregulation inhibits tumorigenesis and enhances TRAIL-induced apoptosis in lung cancer. PLoS ONE 2013 8 6 2-s2.0-84879267458 10.1371/journal.pone.0067581 e67581
170. Condorelli G., Vigliotta G., Cafieri A., Trencia A., Andalò P., Oriente F., Miele C., Caruso M., Formisano P., Beguinot F., PED/PEA-15: an anti-apoptotic molecule that regulates FAS/TNFR1-induced apoptosis. Oncogene 1999 18 31 4409 4415 2-s2.0-0033527064 10.1038/sj.onc.1202831 (Pubitemid 29396648)
171. Condorelli G., Vigliotta G., Iavarone C., Caruso M., Tocchetti C. G., Andreozzi F., Cafieri A., Tecce M. F., Formisano P., Beguinot L., Beguinot F., PED/PEA-15 gene controls glucose transport and is overexpressed in type 2 diabetes mellitus. The EMBO Journal 1998 17 14 3858 3866 2-s2.0-0032527747 10.1093/emboj/17.14.3858 (Pubitemid 28333972)
172. Renault F., Formstecher E., Callebaut I., Junier M.-P., Chneiweiss H., The multifunctional protein PEA-15 is involved in the control of apoptosis and cell cycle in astrocytes. Biochemical Pharmacology 2003 66 8 1581 1588 2-s2.0-0642314376 10.1016/S0006-2952(03)00514-8 (Pubitemid 38373349)
173. Kitsberg D., Formstecher E., Fauquet M., Kubes M., Cordier J., Canton B., Pan G., Rolli M., Glowinski J., Chneiweiss H., Knock-out of the neural death effector domain protein PEA-15 demonstrates that its expression protects astrocytes from TNF α -induced apoptosis. Journal of Neuroscience 1999 19 19 8244 8251 2-s2.0-0033216124 (Pubitemid 30226743)
174. Zanca C., Garofalo M., Quintavalle C., Romano G., Acunzo M., Ragno P., Montuori N., Incoronato M., Tornillo L., Baumhoer D., Briguori C., Terracciano L., Condorelli G., PED is overexpressed and mediates TRAIL resistance in human non-small cell lung cancer. Journal of Cellular and Molecular Medicine 2008 12 6A 2416 2426 2-s2.0-55549124430 10.1111/j.1582-4934.2008.00283.x
175. Incoronato M., Garofalo M., Urso L., Romano G., Quintavalle C., Zanca C., Iaboni M., Nuovo G., Croce C. M., Condorelli G., miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. Cancer Research 2010 70 9 3638 3646 2-s2.0-77951716642 10.1158/0008-5472.CAN-09-3341